Background
The RV144 vaccine trial correlated antibody-dependent cellular cytotoxicity (ADCC) with a reduced risk of HIV infection, highlighting the association between Fc-mediated responses and protective immunity. A promising approach to optimizing ADCC induction is to enhance the exposure of CD4-inducible (CD4i) epitopes, which are responsible for eliciting ADCC responses, on the HIV-1 envelope. These epitopes are typically occluded but become exposed upon CD4 binding. In this study, we describe a prototype vaccine based on the viral envelope presented on virus-like particles (VLPs), designed to maximize CD4i epitope exposure through modification of the VLP surface via incorporation of CD4 molecules.
Methods
Generation of VLPs was achieved by transient co-transfection of expression vectors encoding Env [AC10.29 (subtype B, Tier 2), ConM (group M consensus), and 763 (from an individual with bNAbs during early infection)], furin, optimized HIV-1 Gag as a T-cell immunogen, and CD4. Particle size distribution was determined using nanoparticle tracking analysis (NTA). Env and CD4 incorporation was assessed by Western blotting and immunoelectron microscopy, antigenicity was evaluated by ELISAs using bNAbs [2F5 (MPER), VRC01 (CD4bs), and PG16 (V2)] and CD4i antibodies (17b, 48d, and A32), and ADCC activity was measured via FcγRIIIa activation with pools of HIV postive and negative sera in Jurkat-Lucia™ NFAT-CD16 cells.
Results
CD4 was efficiently incorporated into the VLPs (Figure a) without affecting particle diameter (156.0–178.1 nm), although Env incorporation was reduced by 18.1–51.0%. CD4-VLPs exhibited a 2.0–5.0-fold increase in binding to CD4i antibodies per spike while maintaining binding to the tested bNAbs, albeit with a moderate reduction in affinity (1.3–4.2-fold). Notably, CD4 incorporation also led to a 2.7-fold increase in FcγRIIIa activation per spike, indicative of enhanced ADCC responses (Figure b).
Conclusions
Modifying the design of an HIV-1 VLP-based vaccine prototype through incorporation of CD4 molecules enhances its capacity to induce ADCC responses by 2.7-fold while preserving recognition of epitopes targeted by bNAbs. Our data support the use of CD4-VLPs as a novel platform for the design of vaccine prototypes aimed at improving the induction of Fc-mediated responses.
Table or Figure
